Trends in blood transfusion among hospitalized children with sickle cell disease
- PMID: 23775719
- PMCID: PMC4091906
- DOI: 10.1002/pbc.24630
Trends in blood transfusion among hospitalized children with sickle cell disease
Abstract
Background: Blood transfusions represent a major therapeutic option in acute management of sickle cell disease (SCD). Few data exist documenting trends in transfusion among children with SCD, particularly during hospitalization.
Procedure: This was an analysis of cross-sectional data of hospital discharges within the Kid's Inpatient Database (years 1997, 2000, 2003, 2006, 2009). Hospitalizations for children (0-18 years) with a primary or secondary SCD-related diagnosis were examined. The primary outcome was blood transfusion. Trends in transfusion were assessed using weighted multivariate logistic regression in a merged dataset with year as the primary independent variable. Co-variables consisted of child and hospital characteristics. Multivariate logistic regression was conducted for 2009 data to assess child and hospital-level factors associated with transfusion.
Results: From 1997 to 2009, the percentage of SCD-related hospitalizations with transfusion increased from 14.2% to 28.8% (P < 0.0001). Among all SCD-related hospitalizations, the odds of transfusion increased over 20% for each successive study interval. Hospitalizations with vaso-occlusive pain crisis (OR 1.35, 95% CI 1.27-1.43) or acute chest syndrome/pneumonia (OR 1.24, 95% CI 1.13-1.35) as the primary diagnoses had the highest odds of transfusion for each consecutive study interval. Older age and male gender were associated with higher odds of transfusion.
Conclusions: Blood transfusion is increasing over time among hospitalized children with SCD. Further study is warranted to identify indications contributing to the rise in transfusions and if transfusions in the inpatient setting have been used appropriately. Future studies should also assess the impact of rising trends on morbidity, mortality, and other health-related outcomes.
Keywords: epidemiology; health care utilization; outcomes research; sickle cell disease.
Copyright © 2013 Wiley Periodicals, Inc.
Conflict of interest statement
Conflict of interest: Nothing to declare.
Figures
Similar articles
-
Preoperative blood transfusions for sickle cell disease.Cochrane Database Syst Rev. 2020 Jul 2;7(7):CD003149. doi: 10.1002/14651858.CD003149.pub4. Cochrane Database Syst Rev. 2020. PMID: 32614473 Free PMC article.
-
High resource hospitalizations among children with vaso-occlusive crises in sickle cell disease.Pediatr Blood Cancer. 2012 Apr;58(4):584-90. doi: 10.1002/pbc.23181. Epub 2011 May 16. Pediatr Blood Cancer. 2012. PMID: 21584938 Clinical Trial.
-
Shorter hospitalization trends among children with sickle cell disease.Pediatr Blood Cancer. 2012 Oct;59(4):679-84. doi: 10.1002/pbc.24065. Epub 2012 Jan 4. Pediatr Blood Cancer. 2012. PMID: 22223395
-
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.JAMA. 2014 Sep 10;312(10):1033-48. doi: 10.1001/jama.2014.10517. JAMA. 2014. PMID: 25203083 Review.
-
The clinical effectiveness and cost-effectiveness of primary stroke prevention in children with sickle cell disease: a systematic review and economic evaluation.Health Technol Assess. 2012;16(43):1-129. doi: 10.3310/hta16430. Health Technol Assess. 2012. PMID: 23140544 Free PMC article. Review.
Cited by
-
Acute Complications of Sickle Cell Disease in Children Under 5 Years at a Level II Hospital.Glob Pediatr Health. 2022 Dec 8;9:2333794X221141356. doi: 10.1177/2333794X221141356. eCollection 2022. Glob Pediatr Health. 2022. PMID: 36518586 Free PMC article.
-
Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study.Blood Adv. 2022 Feb 22;6(4):1243-1254. doi: 10.1182/bloodadvances.2021004938. Blood Adv. 2022. PMID: 34847228 Free PMC article. Clinical Trial.
-
"A child with sickle cell disease can't live with just anyone." A mixed methods study of socio-behavioral influences and severity of sickle cell disease in northern Nigeria.Health Sci Rep. 2020 Dec 23;4(1):e222. doi: 10.1002/hsr2.222. eCollection 2021 Mar. Health Sci Rep. 2020. PMID: 33376812 Free PMC article.
-
Blood Transfusion Frequency and Indications in Yemeni Children with Sickle Cell Disease.Anemia. 2020 Aug 24;2020:7080264. doi: 10.1155/2020/7080264. eCollection 2020. Anemia. 2020. PMID: 32908695 Free PMC article.
-
Sickle cell disease: when and how to transfuse.Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):625-631. doi: 10.1182/asheducation-2016.1.625. Hematology Am Soc Hematol Educ Program. 2016. PMID: 27913538 Free PMC article. Review.
References
-
- The Management of Sickle Cell Disease. National Institutes of Health: National Heart, Lung, and Blood Institute; 2002. Report. NIH Publication No. 02-2117.
-
- Frank NC, Allison SM, Cant MEC. Sickle cell disease. In: Brown RT, editor. Cognitive aspects of chronic illness in children. New York: Guilford Press; 1999. pp. 172–189.
-
- Smith JA. The natural history of sickle cell disease. Ann N Y Acad Sci. 1989;565:104–108. - PubMed
-
- Josephson CD, Su LL, Hillyer KL, et al. Transfusion in the patient with sickle cell disease: A critical review of the literature and transfusion guidelines. Transfus Med Rev. 2007;21:118–133. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
